Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

PURPOSE: The Wee1 kinase inhibitor adavosertib abrogates cell cycle arrest, leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid tumors determined the recommended phase 2 dose (RPh2D). Here, we report results for once-daily adavosertib. PATIENTS AND METHODS...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Takebe, Naoko, Naqash, Abdul Rafeh, Coyne, Geraldine O’Sullivan, Kummar, Shivaani, Do, Khanh, Bruns, Ashley, Juwara, Lamin, Zlott, Jennifer, Rubinstein, Larry, Piekarz, Richard, Sharon, Elad, Streicher, Howard, Mittra, Arjun, Miller, Sarah B., Ji, Jiuping, Wilsker, Deborah, Kinders, Robert J., Parchment, Ralph E., Chen, Li, Chang, Ting-Chia, Das, Biswajit, Mugundu, Ganesh, Doroshow, James H., Chen, Alice P.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8282703/
https://ncbi.nlm.nih.gov/pubmed/33863809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-21-0329
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia